CeloNova BioSciences has announced that the US FDA has granted approval to start an investigational device exemption (IDE) clinical trial for its Oncozene embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of hepatocellular carcinoma.
Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states.
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options.
Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea.
BTG and its partner SciClone Pharmaceuticals have announced that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularised tumours.
A study group at the Comprehensive Cancer Centre of Medical University of Vienna and AKH Vienna under the guidance of Maria Sibilia from the Institute for Cancer Research has discovered that tumorigenisis of epidermal growth factor receptor (EGFR) does not, as previously assumed, depend on its presence within the tumour cell, but rather from its activity in the cells adjacent to the tumour.
Despite the rapid growth of imaging and treatment options in interventional oncology, one area that has been poorly understood and overlooked by the interventional community is the role of the tumour microenvironment and its impact on the delivery of therapeutic agents, writes Aravind Arepally.
The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star (DFINE) tumour ablation system.
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or small intestine can result in serious complications, especially gastrointestinal ulcerations, particularly with Y-90 microspheres. Now, temporary antireflux devices are available that appear to provide both adequate retrograde and antegrade protection against nontarget delivery of cytotoxic agents,
Over the years, we have seen a rapid development of tools, tricks and techniques that enable ablation of tumours located in regions that are in close proximity to thermally sensitive organs or structures, writes Nishita Kothary (Stanford University, USA).
Preliminary observations from the trial were presented at the Global Embolization Symposium and Technologies US (GEST US meeting, 1–4 May, San Francisco, USA) and show increased tumour penetration with the Surefire system.
Interventional radiology techniques are widely performed and useful in liver metastases from neuroendocrine tumours, but the level of scientific proof is paradoxically low, especially when considering that these techniques are used in patients with cancer, write Maxime Ronot and Valérie Vilgrain
Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling.
Yasuaki Arai, director of the National Cancer Center Hospital, Tokyo, Japan, and current president of the Japanese Society of Interventional Radiology (JSIR), delivered the Honorary Lecture at the E...
An overview of three treatments: ablation, chemoembolization and selective interval radiation therapy, should clarify the challenges of determining tumour response in interventional oncology, write M...